Alixorexton

Alixorexton
Clinical data
Other namesALKS-2680; ALKS2680
Routes of
administration
Oral
Drug classOrexin OX2 receptor agonist; Wakefulness-promoting agent
Identifiers
  • N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
KEGG
Chemical and physical data
FormulaC21H30N2O5S
Molar mass422.54 g·mol−1
3D model (JSmol)
  • O=C1N2CCC[C@@H]([C@@H]2CO[C@@H]3CC[C@@H](CC3)C4=C(OC1)C=CC=C4)NS(=O)(C)=O
  • InChI=1S/C21H30N2O5S/c1-29(25,26)22-18-6-4-12-23-19(18)13-27-16-10-8-15(9-11-16)17-5-2-3-7-20(17)28-14-21(23)24/h2-3,5,7,15-16,18-19,22H,4,6,8-14H2,1H3/t15?,16?,18-,19-/m0/s1
  • Key:IHNJMACFBQEKRJ-VHZYLWGESA-N

Alixorexton (INNTooltip International Nonproprietary Name; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia. Alixorexton is being developed by Alkermes As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1.

See also